BTIG lowered the firm’s price target on NeoGenomics (NEO) to $12 from $17 and keeps a Buy rating on the shares. The firm cites the company’s Q1 revenue miss and a lower revenue guide for its acquired Pathline business, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics: Hold Rating Amid Mixed Financial Performance and Market Conditions
- NeoGenomics Reports Strong Q1 2025 Performance
- NeoGenomics Reports Strong Q1 2025 Earnings Growth
- Optimistic Buy Rating for NeoGenomics Amid CEO Transition and Growth Potential
- Challenging Growth Outlook and Competitive Pressures Lead to Hold Rating for NeoGenomics